T-Mobile Boosts Full-Year Core Adjusted EBITDA Outlook

Published 3 hours agoTMUS

T-Mobile Boosts Full-Year Core Adjusted EBITDA Outlook

T-Mobile has revised its full-year core adjusted EBITDA outlook upwards to a range of $33.2 billion to $33.7 billion. This announcement signals confidence in its financial performance and robust operational metrics as the year progresses.

In the first quarter of 2025, T-Mobile reported a 24% year-over-year increase in net income, amounting to $3.0 billion. Additionally, the company's diluted earnings per share saw a significant rise of 29%, reaching $2.58 compared to $2.00 in the first quarter of 2024. Service revenues also climbed to $16.9 billion, reflecting a 5% growth, supported by an 8% increase in postpaid service revenue.

For the full year, T-Mobile expects service revenue growth of around 5% and postpaid customer net additions between 5.5 million and 6 million. The company anticipates a cash capital expenditure of approximately $9.5 billion, while adjusted free cash flow is projected to be between $17.3 billion and $18 billion. T-Mobile maintains industry leadership through its effective network performance and strategic focus on customer growth, as noted by financial reports.

Share this article

Twitter Facebook LinkedIn

Recent Articles

FDA Fast-Tracks Review of Gilead's Lenacapavir for HIV Prevention

FDA Fast-Tracks Review of Gilead's Lenacapavir for HIV Prevention

11 minutes agoGILD

The U.S. Food and Drug Administration has accepted Gilead Sciences' New Drug Application for lenacapavir as a twice-yearly injectable for pre-exposure prophylaxis (PrEP) of HIV-1, assigning it a priority review status. A target action date is set for June 19, 2025, under the Prescription Drug User Fee Act, marking a significant milestone for the potential approval of this innovative treatment. Gilead is preparing for a possible mid-2025 launch of lenacapavir for PrEP, aiming for widespread access within six to twelve months post-approval. If successful, lenacapavir would be the first and only twice-yearly prevention option available, transforming the current HIV prevention treatment landscape. The company's strategy is significant given the ongoing global efforts to improve HIV-1 prevention and patient outcomes. Already approved as Sunlenca for treating multi-drug-resistant HIV, lenacapavir's application has also been submitted to the European Medicines Agency for PrEP consideration under an accelerated assessment process. According to sources such as GlobeNewswire, Gilead is focusing on expanding global access by exploring additional regulatory pathways in low- and lower-middle-income countries, reinforcing its commitment to making PrEP treatments more universally available.

Company's Q1 2025 Earnings Surpass Expectations with 35% Net Income Growth

Company's Q1 2025 Earnings Surpass Expectations with 35% Net Income Growth

26 minutes agoWTBA

The company posted a significant 35% increase in net income for the first quarter of 2025, reaching $7.8 million or $0.46 per share, compared to $5.8 million or $0.35 per share in the same period of 2024. This performance exceeded earnings per share forecasts by 15%, with analysts having expected $0.40 per share. Total revenue for the quarter also surpassed estimates, reaching $23.1 million versus the anticipated $21.7 million. Key financial metrics showed positive developments, with the net interest margin rising to 2.28% from 1.98% in the previous quarter, indicating improved profitability from the company's lending activities. The efficiency ratio also improved, dropping to 56.37%. Despite market concerns reflected in a 5.39% stock decline to $18.60 post-earnings, the firm maintained robust credit quality, reporting zero loans past due over 90 days and no nonperforming assets, according to the latest quarterly report. The company also strengthened its tangible common equity ratio to 5.97% as its loan portfolio expanded by $11.6 million during the quarter. Demonstrating commitment to returning value to shareholders, it maintained a dividend of $0.25 per share, expected to be paid on May 21, marking 27 consecutive years of consistent payments. According to Insider Monkey, these combined factors underscore the firm's solid financial standing and strategic focus on core banking metrics.

Boston Beer Reaffirms 2025 EPS Guidance Amid Strong Q1 Results

Boston Beer Reaffirms 2025 EPS Guidance Amid Strong Q1 Results

41 minutes agoSAM

Boston Beer has reaffirmed its full-year 2025 earnings per share guidance, projecting a range of $8 to $10.50. This outlook falls short of analyst expectations, which had estimated an EPS of $10.85. The company remains committed to maintaining its trajectory despite the forecasted gap. The craft beer producer reported strong first-quarter financial results, with net revenue climbing 6.5% to $453.9 million, surpassing forecasts. Boston Beer recorded a 108% year-over-year increase in earnings per share, reaching $2.16. Additionally, net income surged by 93.8% to $24.4 million, while an improved gross margin reached 48.3%. With a robust cash position of $152.5 million and no debt, the results signal a solid start to the year. Boston Beer continues to focus on core brand execution and innovations, including the national expansion of its Sun Cruiser line. According to Insider Monkey, the company aims to bolster its market position through strategic advertising and has invested $61 million in share repurchases this year, reflecting confidence in its operational strategy.

Alphabet to Announce Q2 Earnings Amid Revenue Growth Projections

Alphabet to Announce Q2 Earnings Amid Revenue Growth Projections

1 hours agoGOOGL

Alphabet is poised to release its second-quarter earnings on either April 24 or April 25, 2025, depending on varying reports. Investors are keenly awaiting this release as Alphabet is expected to post strong financial results despite broader market uncertainties. The tech giant's revenue is projected to grow by 11%, reaching approximately $89.2 billion. Expectations for net income are set around $24.7 billion, with earnings per share estimated between $2.01 and $2.04. According to sources like The Motley Fool, Alphabet's growth continues to be driven by innovations in artificial intelligence, notably through its Gemini AI, and expanding cloud services. While Alphabet anticipates solid performance, it faces market challenges such as ongoing legal battles that have contributed to a near 20% decline in its stock value year-to-date. Despite these hurdles, the company's strategic focus remains on bolstering its AI capabilities and cloud infrastructure, positioning itself to navigate the fluctuating economic landscape.